NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) Director James N. Topper purchased 8,429 shares of the firm’s stock in a transaction on Tuesday, March 26th. The shares were purchased at an average price of $21.50 per share, with a total value of $181,223.50. Following the completion of the acquisition, the director now directly owns 3,008,429 shares of the company’s stock, valued at $64,681,223.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
NewAmsterdam Pharma Stock Performance
Shares of NAMS traded up $0.95 on Thursday, reaching $23.65. 292,386 shares of the stock traded hands, compared to its average volume of 240,993. NewAmsterdam Pharma has a 12 month low of $5.63 and a 12 month high of $26.35. The stock’s 50-day moving average price is $21.52 and its 200-day moving average price is $14.04.
Hedge Funds Weigh In On NewAmsterdam Pharma
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Fcpm Iii Services B.V. acquired a new position in NewAmsterdam Pharma in the fourth quarter worth $132,157,000. Goldman Sachs Group Inc. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $15,463,000. Opaleye Management Inc. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at $2,964,000. Parkman Healthcare Partners LLC lifted its stake in shares of NewAmsterdam Pharma by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock valued at $3,359,000 after acquiring an additional 51,726 shares during the period. Finally, Royal Bank of Canada lifted its stake in shares of NewAmsterdam Pharma by 987.5% during the fourth quarter. Royal Bank of Canada now owns 10,875 shares of the company’s stock valued at $121,000 after acquiring an additional 9,875 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Report on NAMS
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE).
Further Reading
- Five stocks we like better than NewAmsterdam Pharma
- 5 discounted opportunities for dividend growth investors
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Financial Services Stocks Investing
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Dividend Payout Ratio Calculator
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.